New lipid-lowering drugs: an update

International Journal of Clinical Practice
A S WierzbickiA Viljoen

Abstract

Lipid lowering is established as a proven intervention to reduce atherosclerosis and its complications. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipoprotein cholesterol, for example, thyroid mimetics (thyroid receptor beta-agonists), antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, for example, novel peroxosimal proliferator activating receptors agonists, MTPIs, diacylglycerol acyl transferase-1 inhibitors and high-density lipoprotein cholesterol (HDL-C), for example, mimetic peptides; HDL delipidation strategies and cholesterol ester transfer protein inhibitors and modulators of inflammation, for example, phospholipase inhibitors. Gene therapy for specific rare disorders, for example, lipoprotein lipase deficiency using alipogene tiparvovec is also in clinical trials. Lipid-lowering drugs are likely to prove a fast-developing area for novel treatments as possible synergies exist between new and established compounds for the treatment of atherosclerosis.

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
May 25, 1999·Metabolism: Clinical and Experimental·H Gylling, T A Miettinen
Jun 9, 1999·The Biochemical Journal·E A BiessenT J van Berkel
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 11, 2002·The American Journal of Cardiology·Frank M Sacks, UNKNOWN Expert Group on HDL Cholesterol
Aug 14, 2002·Annals of Medicine·Michael Stumvoll, Hans-Ulrich Häring
Jun 14, 2003·Pharmacology & Therapeutics·Anthony S WierzbickiAlbert Ferro
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Nov 10, 2004·Circulation·Jean-Claude TardifUNKNOWN Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators
Dec 1, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Hubert C Chen, Robert V Farese
Dec 2, 2004·Journal of Molecular and Cellular Cardiology·Eugene MorkinCynthia Adamson
Dec 21, 2004·International Journal of Clinical Practice·A S Wierzbicki
Jan 18, 2005·Journal of the American College of Cardiology·Rakesh S BirjmohunErik S G Stroes
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol
Dec 21, 2005·Heart·UNKNOWN British Cardiac SocietyUNKNOWN Stroke Association
Mar 7, 2006·Journal of the American College of Cardiology·Stephen J NichollsSteven E Nissen
Mar 24, 2006·The New England Journal of Medicine·Steven E NissenUNKNOWN ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Dec 5, 2006·The Journal of Clinical Investigation·Daniel J Rader
Jan 12, 2007·The New England Journal of Medicine·Marina CuchelDaniel J Rader
Mar 28, 2007·The New England Journal of Medicine·Alan R Tall
Mar 28, 2007·JAMA : the Journal of the American Medical Association·Jean-Claude TardifUNKNOWN Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Jun 19, 2007·Biochimica Et Biophysica Acta·Dayami LopezGene C Ness
Sep 13, 2007·JAMA : the Journal of the American Medical Association·Sonal SinghCurt D Furberg
Sep 21, 2007·Atherosclerosis·Ian GrahamUNKNOWN ESC Committee for Practice Guidelines
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
May 27, 2008·Lancet·Jean-Claude TardifUNKNOWN Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators
May 29, 2008·Nature Clinical Practice. Cardiovascular Medicine·Frederick F SamahaDaniel J Rader
Aug 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maria Frank-KamenetskyKevin Fitzgerald
Aug 19, 2008·International Journal of Clinical Practice·A S Wierzbicki
Sep 4, 2008·Circulation·Patrick W SerruysUNKNOWN Integrated Biomarker and Imaging Study-2 Investigators
Sep 16, 2008·Thrombosis Research·Frank HermannThomas F Lüscher

❮ Previous
Next ❯

Citations

Dec 18, 2012·Current Atherosclerosis Reports·Willibald Hochholzer, Robert P Giugliano
Jan 12, 2013·Current Atherosclerosis Reports·Binh An P Phan, Peter P Toth
May 31, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Caroline M Perry
Feb 19, 2013·European Heart Journal·G Kees HovinghAnne M O'Connor
May 23, 2012·International Journal of Clinical Practice·A S Wierzbicki
Jul 3, 2013·Current Cardiology Reports·James BarnettAnthony S Wierzbicki
Oct 17, 2014·Expert Opinion on Pharmacotherapy·Anthony S Wierzbicki, Adie Viljoen
Sep 10, 2013·Expert Opinion on Pharmacotherapy·Manfredi RizzoJose Lopez-Miranda
Nov 7, 2012·Expert Opinion on Biological Therapy·Anthony S Wierzbicki, Adie Viljoen
Apr 13, 2012·Expert Opinion on Investigational Drugs·Anthony S WierzbickiAdie Viljoen
Nov 10, 2015·Clinical Therapeutics·Damon A Bell, Gerald F Watts
Jun 14, 2013·International Journal of Clinical Practice·A S Wierzbicki
Apr 12, 2013·International Journal of Clinical Practice·Anthony S Wierzbicki
Apr 9, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jonathan D SchofieldHandrean Soran
Sep 9, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Yitong ZhuYuan Zhong
Mar 4, 2015·Nature Reviews. Endocrinology·Amanda J Brahm, Robert A Hegele
Dec 4, 2014·Clinical Medicine : Journal of the Royal College of Physicians of London·Anthony S WierzbickiMfon Ewang-Emukowhate
Nov 26, 2013·American Journal of Human Genetics·Elisabeth A RosenthalGail P Jarvik
Apr 5, 2014·Clinical Pharmacology and Therapeutics·R HajhosseinyA S Wierzbicki
Jan 31, 2015·Current Opinion in Lipidology·Elisabeth RosenthalGail P Jarvik
May 30, 2014·Current Opinion in Cardiology·Devaki R NairKhalid Al-Rasadi
Jun 6, 2013·Current Opinion in Cardiology·Anthony S WierzbickiDimitri P Mikhailidis
Jun 6, 2013·Current Opinion in Cardiology·Jonathan D SchofieldHandrean Soran
Jul 3, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·Mfon Ewang-Emukowhate, Anthony S Wierzbicki
Sep 4, 2021·Mediators of Inflammation·Jichun HanYunyun Yue

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.